Related to Amylin, Lilly Confirm EU Approval of Byetta as Adjunct to Insulin for Type 2 Diabetes

• EC Approves Roche’s RoActemra for Treating Active Systemic Juvenile Idiopathic Arthritis
  
• EC Approves BI’s Pradaxa for Preventing Stroke in Atrial Fibrillation Patients
  
• Amylin and Takeda Shelve Phase II-Stage Combination Obesity Candidate
  
• EC Clears Roche’s Tarceva as Monotherapy Against Metastatic NSCLC with EGFR Mutations
  
• Qiagen and Lilly to Co-Develop Companion Diagnostic for JAK2 Inhibitor Candidate
  
• EC Clears Novartis’ Afinitor for Treating Advanced Pancreatic NET
  
• EC Clears Janssen-Cilag’s Zytig as Combination Therapy for Castration-Resistant Prostate Cancer
  
• FDA Clears Lilly’s Cialis for Treating Symptoms of BPH in Men with or without Erectile Dysfunction
  
• EC Clears Pfizer’s Pneumococcal Vaccine for Use in Individuals Over Age 50
  
• EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• EC Clears Novartis’ Blood Pressure Therapy
  
• EC Clears Gilead’s Single-Pill Triple-Drug HIV-1 Therapy
  
• Nearly Two-to-One Majority Sees FDA or EMA Approval of Gene Therapy by 2013
  
• Roche’s Cobas EGFR Mutation Test Granted CE Mark
  
• EC Clears Roche’s Avastin Against Ovarian Cancer
  
• Roche Gets CE Clearance for Two HCV Molecular Diagnostics
  
• FDA Asks BMS, AstraZeneca for More Clinical Data for Antidiabetic
  
• EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS
  
• EC Clears Roche, Plexxikon’s Zelboraf for BRAF V600-Mutated Melanoma